BioGaia Logo

BioGaia

ISIN: SE0017769995 | Ticker: BIOG | LEI: 549300UBUJOY2L7TT361
Sector: Health CareSub-Industry: Biotechnology
Country: Sweden

About BioGaia

Company Description

BioGaia is an innovative Swedish health care company and a world leader in probiotics. The company has more than 20 years experience in the field of probiotics that promote people’s health. BioGaia's products combine the well researched probiotic bacteria Lactobacillus reuteri and top of the line engineering to develop unique packaging solutions that make it possible to create probiotic products that match consumer needs. The class B share of BioGaia is quoted on the Mid Cap list of the Nordic Exchange Stockholm.

Year founded

1990

Served area

Worldwide

Headquarters

Kungsbroplan 3, 11227 Stockholm – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 1,913,282,000.00 2,128,054,000.00 2,213,966,000.00
Noncurrent Assets N/A 223,705,000.00 375,977,000.00 416,485,000.00
Property Plant And Equipment N/A 133,904,000.00 138,555,000.00 144,168,000.00
Goodwill N/A 5,300,000.00 149,227,000.00 171,517,000.00
Intangible Assets Other Than Goodwill N/A 50,322,000.00 48,086,000.00 46,075,000.00
Deferred Tax Assets N/A 5,279,000.00 2,757,000.00 15,325,000.00
Other Noncurrent Financial Assets N/A 0.00 22,229,000.00 25,793,000.00
Noncurrent Noncash Assets Pledged As Collateral For Which Transferee Has Right By Contract Or Custom To Sell Or Repledge Collateral N/A 39,000.00 43,000.00 50,000.00
Current Assets N/A 1,689,577,000.00 1,752,077,000.00 1,797,481,000.00
Inventories N/A 72,277,000.00 102,737,000.00 142,838,000.00
Current Trade Receivables N/A 98,511,000.00 118,588,000.00 130,703,000.00
Current Prepaid Expenses N/A N/A 9,768,000.00 16,841,000.00
Other Current Receivables N/A 41,538,000.00 36,304,000.00 18,733,000.00
Cash and cash equivalents 213,831,000.00 1,467,883,000.00 1,484,680,000.00 1,488,366,000.00
Equity And Liabilities N/A 1,913,282,000.00 2,128,054,000.00 2,213,966,000.00
Equity 507,874,000.00 1,746,245,000.00 1,877,367,000.00 1,972,418,000.00
Issued Capital N/A 20,196,000.00 20,196,000.00 20,196,000.00
Additional Paidin Capital N/A 1,149,483,000.00 1,154,008,000.00 1,153,794,000.00
Equity Attributable To Owners Of Parent N/A 1,746,243,000.00 1,877,365,000.00 1,972,416,000.00
Noncontrolling Interests N/A 2,000.00 2,000.00 2,000.00
Liabilities N/A 167,037,000.00 250,687,000.00 241,548,000.00
Noncurrent Liabilities N/A 31,975,000.00 123,733,000.00 76,557,000.00
Deferred Tax Liabilities N/A 11,312,000.00 14,240,000.00 12,552,000.00
Other Noncurrent Liabilities N/A 20,663,000.00 109,493,000.00 64,005,000.00
Current Liabilities N/A 135,062,000.00 126,954,000.00 164,991,000.00
Trade And Other Current Payables N/A 48,046,000.00 42,313,000.00 32,050,000.00
Current Advances N/A 11,184,000.00 2,815,000.00 9,171,000.00
Current Tax Liabilities Current N/A 1,170,000.00 4,479,000.00 22,715,000.00
Other Current Liabilities N/A 25,939,000.00 20,948,000.00 23,110,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 747,077,000.00 785,110,000.00 1,103,957,000.00
Other Income 1,084,000.00 11,604,000.00 27,489,000.00
Profit Loss From Operating Activities 228,150,000.00 253,737,000.00 361,459,000.00
Finance Income 155,000.00 107,000.00 91,540,000.00
Finance Costs 722,000.00 1,132,000.00 5,386,000.00
Profit Loss Before Tax 227,583,000.00 252,712,000.00 447,613,000.00
Income Tax Expense Continuing Operations 47,853,000.00 56,439,000.00 73,840,000.00
Profit (loss) 179,730,000.00 196,273,000.00 373,773,000.00
Profit Loss Attributable To Owners Of Parent 179,730,000.00 196,273,000.00 373,773,000.00
Profit Loss Attributable To Noncontrolling Interests 0.00 0.00 0.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 179,730,000.00 196,273,000.00 373,773,000.00
Adjustments For Decrease Increase In Inventories N/A -2,347,000.00 9,822,000.00 -34,125,000.00
Adjustments For Decrease Increase In Other Operating Receivables N/A 47,043,000.00 -17,965,000.00 -12,403,000.00
Adjustments For Increase Decrease In Trade Account Payable N/A 19,798,000.00 -6,151,000.00 -12,369,000.00
Adjustments For Increase Decrease In Other Operating Payables N/A -15,471,000.00 12,146,000.00 54,256,000.00
Adjustments For Depreciation And Amortisation Expense N/A 20,530,000.00 27,241,000.00 23,890,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A -4,876,000.00 2,403,000.00 0.00
Other Adjustments For Noncash Items N/A 1,167,000.00 -2,356,000.00 -9,103,000.00
Cash Flows From Used In Operations N/A 244,971,000.00 281,025,000.00 376,246,000.00
Interest Paid Classified As Operating Activities N/A 803,000.00 1,132,000.00 5,386,000.00
Interest Received Classified As Operating Activities N/A 157,000.00 64,000.00 7,634,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 72,092,000.00 55,934,000.00 54,910,000.00
Cash Flows From Used In Operating Activities N/A 221,256,000.00 221,875,000.00 318,943,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 0.00 98,359,000.00 0.00
Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities N/A 0.00 22,229,000.00 225,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 16,075,000.00 6,379,000.00 17,916,000.00
Cash Flows From Used In Investing Activities N/A -16,075,000.00 -126,967,000.00 -18,141,000.00
Proceeds From Issuing Shares N/A 1,126,840,000.00 4,525,000.00 -214,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 0.00 7,174,000.00 0.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 7,632,000.00 7,527,000.00 9,143,000.00
Dividends Paid Classified As Financing Activities N/A 65,012,000.00 68,870,000.00 301,331,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities N/A -2,800,000.00 -2,800,000.00 -2,900,000.00
Cash Flows From Used In Financing Activities N/A 1,051,396,000.00 -81,846,000.00 -313,588,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 1,256,577,000.00 13,062,000.00 -12,786,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -2,525,000.00 3,735,000.00 16,472,000.00
Cash and cash equivalents 213,831,000.00 1,467,883,000.00 1,484,680,000.00 1,488,366,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
02.08.23 Anthon Jahreskog Other Buy SEK 51,515.10
02.08.23 Anthon Jahreskog Other Buy SEK 18,083.00

Capital markets information

ISIN

SE0017769995

LEI

549300UBUJOY2L7TT361

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.